Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 3/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 3/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CPS1 | P31327 | 1/20 | 0.32 |
| ▸ | CASP3 | P42574 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL587629 | 0.95 | ALDH1A1 (0.34) | P2RX7HPGDNPSR1HSD17B10 | |
| SCHEMBL580874 | 0.90 | CHRNB4 (0.35) | NOTUMCHRNB4CHRNA3 | |
| SCHEMBL587299 | 0.90 | DPP4 (0.36) | P2RX7NPSR1 | |
| SCHEMBL581653 | 0.88 | NOTUM (0.37) | NOTUM | |
| SCHEMBL580676 | 0.88 | FFAR2 (0.41) | P2RX7HCRTR2 | |
| SCHEMBL586626 | 0.86 | OPRK1 (0.37) | NPSR1CHRNB4CHRNA3 | |
| SCHEMBL3081192 | 0.85 | NOTUM (0.37) | NOTUMCHRM2KDM4EUSP2HPGD | |
| SCHEMBL580878 | 0.85 | OPRK1 (0.40) | NOTUMCHRNA3 | |
| SCHEMBL586775 | 0.84 | MAPT (0.36) | NOTUMHPGDNPSR1HSD17B10 | |
| SCHEMBL587515 | 0.84 | FFAR2 (0.39) | P2RX7HCRTR2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102459246-B | Isoxazol-3 (2H) -one analogs as therapeutic agents | ASTRAZENECA AB | 2014-05-07 | — | — | CN | disclosed |
| US-8415378-B2 | Isoxazol-3(2H)-one analogs as therapeutic agents | ASTRAZENECA AB (SE) | 2013-04-09 | — | — | US | disclosed |
| EP-2417131-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010117323-A1 | METHOD AND APPARATUS FOR PRODUCING HEAT ENERGY AND CARBON DIOXIDE | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | WO | disclosed |
| US-20100261755-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261755-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | NR4A3, CBR3, OXER1 | P2RX7 873/4885NOTUM 2559/4885HCRTR2 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.